Personalized venlafaxine dose prediction using artificial intelligence technology: a retrospective analysis based on real-world data
Authors:
- 11 May 2024
- journal article
- research article
- Published by Springer Nature in International Journal of Clinical Pharmacy
- Vol. 46 (4) , 926-936
Abstract
Background Venlafaxine dose regimens vary considerably between individuals, requiring personalized dosing. Aim This study aimed to identify dose-related influencing factors of venlafaxine through real-world data analysis and to construct a personalized dose model using advanced artificial intelligence techniques. Method We conducted a retrospective study on patients with depression treated with venlafaxine. Significant variables were selected through a univariate analysis. Subsequently, the predictive performance of seven models (XGBoost, LightGBM, CatBoost, GBDT, ANN, TabNet, and DT) was compared. The algorithm that demonstrated optimal performance was chosen to establish the dose prediction model. Model validation used confusion matrices and ROC analysis. Additionally, a dose subgroup analysis was conducted. Results A total of 298 patients were included. TabNet was selected to establish the venlafaxine dose prediction model, which exhibited the highest performance with an accuracy of 0.80. The analysis identified seven crucial variables correlated with venlafaxine daily dose, including blood venlafaxine concentration, total protein, lymphocytes, age, globulin, cholinesterase, and blood platelet count. The area under the curve (AUC) for predicting venlafaxine doses of 75 mg, 150 mg, and 225 mg were 0.90, 0.85, and 0.90, respectively. Conclusion We successfully developed a TabNet model to predict venlafaxine doses using real-world data. This model demonstrated substantial predictive accuracy, offering a personalized dosing regimen for venlafaxine. These findings provide valuable guidance for the clinical use of the drug.Keywords
Funding Information
- Finance Department of Hebei Province in China (ZF2023020)
- Medical Science Research Project of Hebei Health Commission (20221440)
This publication has 38 references indexed in Scilit:
- Effect of Cytochrome P450 Enzyme Polymorphisms on Pharmacokinetics of VenlafaxineTherapeutic Drug Monitoring, 2011
- On the influence of protein binding on pharmacological activity of drugsJournal of Pharmaceutical Sciences, 2010
- Effects of venlafaxine and fluoxetine on lymphocyte subsets in patients with major depressive disorder: A flow cytometric analysisProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2010
- Taurine Transporter in Lymphocytes of Patients with Major Depression Treated with Venlafaxine Plus Psychotherapy2009
- On the Calculation of the Concentration Dependence of Drug Binding to Plasma Proteins with Multiple Binding Sites of Different Affinities: Determination of the Possible Variation of the Unbound Drug Fraction and Calculation of the Number of Binding Sites of the ProteinJournal of Pharmaceutical Sciences, 2007
- Differential physiological effects of a low dose and high doses of venlafaxine in major depressionInternational Journal of Neuropsychopharmacology, 2006
- Monitoring drug–protein interactionClinica Chimica Acta, 2006
- Evidence of the Dual Mechanisms of Action of VenlafaxineArchives of General Psychiatry, 2000
- O- and N-demethylation of Venlafaxine In Vitro by Human Liver Microsomes and by Microsomes from cDNA-Transfected Cells Effect of Metabolic Inhibitors and SSRI AntidepressantsNeuropsychopharmacology, 1999
- Venlafaxine: A Structurally Unique and Novel AntidepressantAnnals of Pharmacotherapy, 1995